EyeGate Pharmaceuticals Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyeGate Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EyeGate Pharmaceuticals stock.
View analyst ratings for EyeGate Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given EyeGate Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but EyeGate Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

EyeGate Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 81,500 shares, an increase of 49.5% from the August 15th total of 54,500 shares. Based on an average daily trading volume, of 1,780,000 shares, the days-to-cover ratio is presently 0.0 days.
View EyeGate Pharmaceuticals' Short Interest.

EyeGate Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for EyeGate Pharmaceuticals.

EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) issued its quarterly earnings data on Thursday, August, 12th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.07.
View EyeGate Pharmaceuticals' earnings history.

EyeGate Pharmaceuticals' stock was trading at $5.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EYEG shares have decreased by 60.2% and is now trading at $2.00.
View which stocks have been most impacted by COVID-19.

2 equities research analysts have issued 12 month price objectives for EyeGate Pharmaceuticals' stock. Their forecasts range from $9.50 to $11.00. On average, they expect EyeGate Pharmaceuticals' share price to reach $10.25 in the next twelve months. This suggests a possible upside of 412.5% from the stock's current price.
View analysts' price targets for EyeGate Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to EyeGate Pharmaceuticals include Corvus Pharmaceuticals (CRVS), NeuroBo Pharmaceuticals (NRBO), LifeVantage (LFVN), Aadi Bioscience (AADI), Celsion (CLSN), Aptorum Group (APM), Moleculin Biotech (MBRX), Gain Therapeutics (GANX), Ocuphire Pharma (OCUP), Helix BioPharma (HBPCF), Akari Therapeutics (AKTX), OncoSec Medical (ONCS), Ainos (AIMD), Emmaus Life Sciences (EMMA) and Adial Pharmaceuticals (ADIL).
View all of EYEG's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other EyeGate Pharmaceuticals investors own include Bausch Health Companies (BHC), MannKind (MNKD), Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), Celldex Therapeutics (CLDX), Novavax (NVAX), SCYNEXIS (SCYX), Trevena (TRVN), Exelixis (EXEL) and Gilead Sciences (GILD).

(EYEG) raised $5 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.

EyeGate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

EyeGate Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.80%) and Renaissance Technologies LLC (1.27%). Company insiders that own EyeGate Pharmaceuticals stock include Armistice Capital Master Fund, Armistice Capital, Llc and Morton Goldberg.
View institutional ownership trends for EyeGate Pharmaceuticals.

EYEG stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for EyeGate Pharmaceuticals or view top insider-selling stocks.

EYEG stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought EyeGate Pharmaceuticals stock in the last two years include Armistice Capital Master Fund, and Armistice Capital, Llc.
View insider buying and selling activity for EyeGate Pharmaceuticals or or view top insider-buying stocks.

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EYEG stock can currently be purchased for approximately $2.00.

EyeGate Pharmaceuticals has a market capitalization of $25.24 million and generates $10,000.00 in revenue each year. The specialty pharmaceutical company earns $-8,090,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.

EyeGate Pharmaceuticals employs 14 workers across the globe.

The official website for EyeGate Pharmaceuticals is www.eyegatepharma.com.

EyeGate Pharmaceuticals is headquartered at 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452.

EyeGate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at (781) 788-8869 or via email at [email protected].